News

Total revenues increased by 3.3%, or 3.9% in local currencies, to $699.2 million in the second quarter of 2006, compared to $676.8 million in Q2 2005. Product sales

The agreement covers the sale of reporter assay kits that use a novel secreted luciferase isolated by Bayer scientists from the marine copepod, Metridia longa. Under the terms

Cambridge Antibody Technology (CAT) obtains access to Molecular Partners’ proprietary designed repeat proteins (DRPs) technology and Molecular Partners gains rights to intellectual property in ribosome display, controlled by

Patanol solution provides both mast cell stabilizing and anti-histamine properties in a single molecule, providing patients with rapid, effective and lasting relief from the signs and symptoms of

According to the study data, there were no meaningful signals of carcinogenicity detected after two years of testing in two species – rats and mice. The company said

The American Lung Association will expand its annual influenza awareness efforts to educate the public about influenza and the need for vaccination through support and resources from Sanofi

The special protocol assessment (SPA) documents the FDA’s agreement regarding the trial’s design and planned analyses to fulfill commitments that may be required under provisions relating to accelerated

In vitro toxicogenomics offers the potential for companies to reduce the attrition rate of compounds due to safety problems in the later stages of drug development, when those

The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition